Home

Ovarian cancer drug will cost HAs millions

2000-05-11T00:00:00

Health authorities will have to find millions of pounds to fund cancer drugs after the National Institute for Clinical Excellence backed the use of paclitaxel to treat patients with ovarian cancer.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here